Evidence map›Paper›PMID 34236477›Full record

ArticleWorld journal of surgery2021

Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma.

Joseph R Habib, Shamsher Pasha, Subhan Khan, Benedict Kinny-Köster, Sami Shoucair, Elizabeth D Thompson, Jun Yu, Kelly Lafaro, Richard A Burkhart, William R Burns and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Joseph R HabibDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shamsher PashaDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Subhan KhanDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Benedict Kinny-KösterDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sami ShoucairDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elizabeth D ThompsonDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jun YuDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kelly LafaroDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Richard A BurkhartDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William R BurnsDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brigitte M RonnettDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christopher L WolfgangDepartment of Surgery, New York University School of Medicine and NYU-Langone Medical Center, New York, NY, USA.
Ralph H HrubanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jin HeDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elliot K Fishman *Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ammar A Javed *Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ajaved1@jhmi.edu.
Johns Hopkins Medicine · USJohns Hopkins University · USNYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) has a high propensity for systemic dissemination. Ovarian metastases are rare and poorly described.

methodsWe identified PDAC cases with ovarian metastasis from a prospectively maintained registry. We reported on the association between outcomes and clinicopathologic factors. Recurrence-free (RFS) and overall survival (OS) were calculated using Kaplan-Meier analysis.

resultsTwelve patients with PDAC and synchronous or metachronous ovarian metastases were identified. Nine patients (75%) underwent pancreatectomy for localized PDAC and developed metachronous ovarian recurrence. The median OS for all patients was 25.4 (IQR:15.4-82.9) months. For the nine patients with metachronous ovarian metastasis, the median RFS and OS were 14.2 (IQR:7.2-58.3) and 44.6 (IQR:18.6-82.9) months, respectively. Nodal disease, poor grade, vascular invasion in the pancreatic primary, and bilateral ovarian disease tended to confer worse outcomes.

conclusionPatients with resected PDAC and ovarian recurrence tend to have a comparable disease course to more common patterns of recurrence. Primaries with nodal disease, poorer grade, vascular invasion, and bilateral ovarian disease were indicative of more aggressive disease biology. The ideal management remains largely unknown, and future collaborative efforts should optimize therapeutic strategies.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalOvarian NeoplasmsPancreatic NeoplasmsFemaleHumansNeoplasm Recurrence, LocalPancreatectomyPrognosisRetrospective Studies

Identifiers

PMID34236477
OpenAlexW3179492611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.